Alexis A. Thompson, MD, MPH

Professor of Pediatrics (Hematology)
Chief, Division of Hematology, Children's Hospital of Philadelphia
Elias Schwartz MD Endowed Chair in Hematology, Children's Hospital of Philadelphia
Department: Pediatrics
Contact information
Department of Pediatrics
Division of Hematology
Children’s Hospital of Philadelphia
3401 Civic Center Blvd
Philadelphia, PA 19104
Division of Hematology
Children’s Hospital of Philadelphia
3401 Civic Center Blvd
Philadelphia, PA 19104
Office: 215 590-2363
Education:
N/A (Zoology)
Pomona College, 1979.
MD (Medicine)
Tulane University School of Medicine, 1983.
MPH (Health Services)
University of California, Los Angeles , 1987.
Permanent linkN/A (Zoology)
Pomona College, 1979.
MD (Medicine)
Tulane University School of Medicine, 1983.
MPH (Health Services)
University of California, Los Angeles , 1987.
Selected Publications
Coleman KD, McKinley K, Ellison AM, Alpern ER, Hariharan S, Topoz I, Wurtz M, Nielsen B, Cook LJ, Morris CR, Brandow AM, Campbell AD, Liem RI, Nuss R, Quinn CT, Thompson AA, Villella A, King AA, Baumann A, Frankenberger W, Brousseau DC; PECARN Registry Working Group: Associations Between Pain Scores and Opioid Doses With Emergency Department Disposition and Return Visit Rates in Children With Sickle Cell Disease. Pediatric Blood Cancer e31750, July 2025 Notes: DOI: 10.1002/pbc.31750.Prussien KV, Burke MM, Gollomp K, Wright RJ, Thompson AA.: Cortisol in Sickle Cell Disease: A Systematic Review and Meta-Analysis. Blood Advance June 2025 Notes: DOI: 10.1182/bloodadvances.2024015425.
Shook LM, Rosen BL, Mara CA, Mosley C, Thompson AA, Smith-Whitley K, Schwartz L, Barriteau C, King A, Oke E, Jallow F, Murphy B, Crosby L.: Attitudes, Beliefs, and Intention to Receive a COVID-19 Vaccine for Pediatric Patients With Sickle Cell Disease. J Pediatr Hematol Onco July 2024.
Kwiatkowski JL, Thompson AA, Tricta F, Temin NT, Rozova A, Fradette C, Badawy SM.: Real-world evidence: Long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years. Am J Hematol. 2024 March 2024.
Gordon RD, Welkie RL, Quaye N, Hankins JS, Kassim AA, Thompson AA, Treadwell M, Lin CJ, Cronin RM. : Burden of employment loss and absenteeism in adults and caregivers of children with sickle cell disease. Blood Adv. January 2024.
Ntoulia A, Darge K, Thompson AA, Back SJ. : Safety of Ultrasound Contrast Agents in Pediatric Patients With Sickle Cell Disease and Trait. J Ultrasound Med January 2024.
Zapfel A, Thompson A, Bridges K, Richardson J, Kasongo L, Przybylski C, Kiyaga C, Barango P, Odame I. : World Coalition on SCD launches, sparking global focus on SCD diagnosis and care. Blood Adv. November 2023.
Coleman KD, McKinley K, Ellison AM, Alpern ER, Hariharan S, Topoz I, Wurtz M, Nielsen B, Cook LJ, Morris CR, Brandow AM, Campbell AD, Liem RI, Nuss R, Quinn CT, Thompson AA, Villella A, King AA, Baumann A, Frankenberger W, Brousseau DC. : Return visit rates after an emergency department discharge for children with sickle cell pain episodes. Pediatr Blood Cancer October 2023.
Sidonio RF Jr, Thompson AA, Peyvandi F, Stasyshyn O, Yeoh SL, Sosothikul D, Antmen AB, Maggiore C, Engl W, Ewenstein B, Tangada S.: Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study. Hematol. September 2023.
Rees CA, Brousseau DC, Cohen DM, Villella A, Dampier C, Brown K, Campbell A, Chumpitazi CE, Airewele G, Chang T, Denton C, Ellison A, Thompson A, Ahmad F, Bakshi N, Coleman KD, Leibovich S, Leake D, Hatabah D, Wilkinson H, Robinson M, Casper TC, Vichinsky E, Morris CR; SCD Arginine Study Group and PECARN.: Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial. Trials August 2023.